RESUMEN
The aim of this research is to assess the effects of metformin and rosiglitazone on clinical symptoms and serum hormonal levels, in obese patients with polycystic ovary syndrome [PCOS]. twenty overweight patients [BMI>25 kg/m2], with polycystic ovary syndrome, were included in this study which has been achieved in Damascus university [2006-2008]. patients were divided into two groups, [RO] included patients being treated with rosiglitazone 4mg/day, and [MO] included patients receiving metformin 850 mg twice a day. The following parameters were calculated and measured, respectively, before and after the treatment: Waist to Hip Ratio W/H Ratio, Body Mass Index [BMI], degree of hirsutism, which was determined by the Ferriman-Gallwey scoring system, Homeostasis Model Assessment of Insulin Resistance [HOMA-IR], hormonal serum levels. In MO group, it was found that BMI, W/H R, HOMA-IR, hormonal serum levels [except DHEA] were significantly reduced, FSH significantly increased. 66.66% of the patients suffering menstrual disturbance became with menstruation regular. Conversely, Rosiglitazone had no statistically significant effects in lowering laboratory values in RO group